45 citations
,
January 2010 in “International journal of trichology” Topical immunotherapy, especially with DPCP, is effective for treating severe alopecia areata.
A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with less inflammation.
48 citations
,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
July 2025 in “International Journal of Trichology” Intralesional methotrexate and triamcinolone acetonide are more effective than Vitamin D3 for treating alopecia areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
April 2026 in “International Journal of Advanced Biochemistry Research” Aegle marmelos fruit extract can protect against arsenic toxicity in mice.
1 citations
,
January 2025 in “Therapeutic Advances in Drug Safety” Antituberculosis drugs can cause severe skin reactions, requiring careful diagnosis and treatment.
9 citations
,
June 2017 in “Pharmacological Reports” ATP-sensitive potassium channels play a role in chloroquine-induced itch in mice.
Ritlecitinib improves hair regrowth in alopecia areata without increasing adverse risks.
New drugs, baricitinib and ritlecitinib, are effective for severe alopecia areata.
20 citations
,
June 2019 in “Archives of dermatological research” Combining DPCP and anthralin helps regrow hair in some alopecia areata patients.
Baricitinib effectively regrows hair in severe alopecia areata cases.
November 2025 in “Mendeley Data” Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.
10 citations
,
August 2019 in “European Journal of Dermatology” The document did not conclude on apremilast's effectiveness for severe alopecia areata.
70 citations
,
July 2020 in “Pharmacological Reports” Cepharanthine, a Japanese hair loss drug, shows promise as a COVID-19 treatment but needs more testing.
4 citations
,
February 2024 in “Anais Brasileiros de Dermatologia”
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
8 citations
,
December 2021 in “BMJ neurology open” Sodium selenate was found to be safe and possibly slows Alzheimer's progression, but more research is needed.
4 citations
,
July 2023 in “Frontiers in Microbiology” HGF combined with ADA is highly accurate for diagnosing tuberculous pleural effusion, especially in younger females.
Oral betamethasone mini-pulses effectively treat moderate to severe alopecia areata with manageable side effects.
September 2024 in “Journal of Cosmetic Dermatology” Combining CGF and microneedling with betamethasone effectively treats resistant alopecia areata.
8 citations
,
January 2020 in “Evidence-based Complementary and Alternative Medicine” Cinobufacin with chemotherapy improves treatment response and quality of life in advanced breast cancer patients while reducing some side effects.
Baricitinib may not always prevent relapse in alopecia areata.
23 citations
,
September 2017 in “Journal of the American Academy of Dermatology” Apremilast did not work for treating severe alopecia areata.
68 citations
,
April 2012 in “Digestive and Liver Disease” Elental is a good long-term treatment for Crohn's disease, similar to 6-mercaptopurine but with fewer side effects.
Betamethasone is more effective long-term for alopecia areata than hydroxychloroquine.
136 citations
,
April 2010 in “British Journal of Dermatology” Acitretin is effective for severe skin conditions but has significant side effects and requires careful monitoring.
1 citations
,
June 2017 in “Journal of the American Academy of Dermatology” Oral tofacitinib may be an effective and tolerable treatment for some people with severe alopecia areata.
June 2017 in “Journal of the American Academy of Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata and related conditions.
3 citations
,
September 2021 in “Journal of Investigative Dermatology” Baricitinib was more effective than a placebo in regrowing hair in adults with alopecia areata after 36 weeks.